» Articles » PMID: 17102939

The Protective Effect of HMG-CoA Reductase Inhibitors Against Monocrotaline-induced Pulmonary Hypertension in the Rat Might Not Be a Class Effect: Comparison of Pravastatin and Atorvastatin

Overview
Specialty Pharmacology
Date 2006 Nov 15
PMID 17102939
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, so called statins, improve endothelial function and exert antiproliferative effects on vascular smooth muscle cells of systemic vessels. This study aimed at comparing the protective effects of two statins, pravastatin and atorvastatin, against monocrotaline (MC)-induced pulmonary hypertension in rats. Pravastatin or atorvastatin (PS or AS, 10 mg/kg per day) or vehicle were given orally for 28 days to Wistar male rats injected or not with MC (60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed severe pulmonary hypertension, with an increase in right ventricular pressure (RVP) and right ventricle/left ventricle + septum weight ratio associated with a decrease in acetylcholine- or sodium-nitroprusside-induced pulmonary artery dilation observed in vitro. Hypertensive pulmonary arteries exhibited an increase in medial thickness and endothelial cell apoptosis and a decrease of endothelial nitric oxide synthase (eNOS) expression. MC-rat lungs showed a significant decrease of eNOS (P < 0.01) and increase of cleaved caspase-3 (P < 0.05) expression determined by Western blotting. PS (P = 0.02) but not AS (P = 0.30) significantly limited the development of pulmonary hypertension (RVP in mmHg: 30 +/- 3, 36 +/- 4 vs. 45 +/- 4 and 14 +/- 1 for MC + PS, MC + AS, MC, and control groups, respectively). Both statins significantly reduced MC-induced right ventricle hypertrophy [RV/left ventricular (LV) + S, in mg/g: 0.46 +/- 0.04, 0.39 +/- 0.03, 0.62 +/- 0.05 and 0.29 +/- 0.01 for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05),and reduced MC-induced thickening (61 +/- 6 microm, 82 +/- 5 microm, 154 +/- 4 microm, and 59 +/- 2 microm for MC + PS, MC + AS, MC, and control groups, respectively; P = 0.01) of small intrapulmonary artery medial wall, with MC + AS still being different from the control group. PS but not AS partially restored acetylcholine-induced pulmonary artery vasodilation in MC rats (E(max)=65 +/- 5%, 49 +/- 6%, 46 +/- 3%, and 76 +/- 4% for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05 for MC + PS vs. other groups). Both statins prevented apoptosis and restored eNOS expression of pulmonary artery endothelial cells as well as in the whole lung with a more pronounced effect with PS compared with AS. In conclusion, despite its effects on eNOS expression, apoptosis, and medial wall thickening, AS was unable to significantly reduce pulmonary hypertension and to restore endothelium-dependent relaxation, suggesting intermolecular differences between the two HMG-CoA reductase inhibitors in the protection against MC-induced hypertension.

Citing Articles

Prognostic value of atherogenic index of plasma in pulmonary hypertension.

Chen M, Wang A, Wan C, Ruan B, Tong J, Shen J Front Med (Lausanne). 2025; 11():1490695.

PMID: 39871832 PMC: 11769793. DOI: 10.3389/fmed.2024.1490695.


Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.

Yuan W, Fan H, Yang H, Tang L, Liu Z, Ouyang F Diagn Pathol. 2023; 18(1):108.

PMID: 37759223 PMC: 10536732. DOI: 10.1186/s13000-023-01393-x.


Role of oxidative stress versus lipids in monocrotaline-induced pulmonary hypertension and right heart failure.

Farahmand F, Malik A, Sharma A, Bagchi A, Singal P Physiol Rep. 2021; 9(22):e15090.

PMID: 34816616 PMC: 8611258. DOI: 10.14814/phy2.15090.


The potential of Atorvastatin for chronic lung diseases therapy.

Tulbah A Saudi Pharm J. 2020; 28(11):1353-1363.

PMID: 33250642 PMC: 7679442. DOI: 10.1016/j.jsps.2020.08.025.


Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis.

Chen F, Yang M, Wan C, Liu L, Chen L Ann Transl Med. 2020; 7(23):786.

PMID: 32042802 PMC: 6990021. DOI: 10.21037/atm.2019.11.19.


References
1.
Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G . Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27(5):589-95. DOI: 10.1093/eurheartj/ehi728. View

2.
Hatanaka T . Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2001; 39(6):397-412. DOI: 10.2165/00003088-200039060-00002. View

3.
Bardou M, Goirand F, Marchand S, Rouget C, Devillier P, Dumas J . Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J Cardiovasc Pharmacol. 2001; 38(2):325-34. DOI: 10.1097/00005344-200108000-00018. View

4.
Martin K, Klinger J, Rounds S . Pulmonary arterial hypertension: new insights and new hope. Respirology. 2006; 11(1):6-17. DOI: 10.1111/j.1440-1843.2006.00778.x. View

5.
Kinlay S . Potential vascular benefits of statins. Am J Med. 2005; 118 Suppl 12A:62-7. DOI: 10.1016/j.amjmed.2005.09.007. View